Skip to content

Study · Randomized controlled trial · 2022

6 results

Chronic nicotinamide mononucleotide supplementation elevates blood nicotinamide adenine dinucleotide levels and alters muscle function in healthy older men.

Igarashi M, Nakagawa-Nagahama Y, Miura M, Kashiwabara K, Yaku K, Sawada M, Sekine R, Fukamizu Y, Sato T, Sakurai T, Sato J, Ino K and 4 more

Show all authors

Kubota N, Nakagawa T, Kadowaki T, Yamauchi T

npj aging1 May 2022Cited by 87 (Europe PMC)

PMID35927255 (opens in a new tab)PMCIDPMC9158788 (opens in a new tab)DOI10.1038/s41514-022-00084-z (opens in a new tab)PepBankPUB-35927255
Download PDFPubMedAsk about this study
Jump to 6 results

Summary

Preclinical studies have revealed that the elevation of nicotinamide adenine dinucleotide (NAD + ) upon the administration of nicotinamide mononucleotide (NMN), an NAD + precursor, can mitigate aging-related disorders; however, human data on this are limited. We investigated whether the chronic oral supplementation of NMN can elevate blood NAD + levels and alter physiological dysfunctions in healthy older participants. We administered 250 mg NMN per day to aged men for 6 or 12 weeks in a placebo-controlled, randomized, double-blind, parallel-group trial. Chronic NMN supplementation was well tolerated and caused no significant deleterious effect. Metabolomic analysis of whole blood samples demonstrated that oral NMN supplementation significantly increased the NAD + and NAD + metabolite concentrations. There were nominally significant improvements in gait speed and performance in the left grip test, which should be validated in larger studies; however, NMN exerted no significant effect on body composition. Therefore, chronic oral NMN supplementation can be an efficient NAD + booster for preventing aging-related muscle dysfunctions in humans.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

  1. 01HumanRandomized controlled trialSafety outcome

    In healthy older men, NMN was well tolerated and caused no significant deleterious effect.

    In plain wordsIn healthy older men, NMN was well tolerated without significant harmful effects.

    Peptide
    NMN (nicotinamide mononucleotide)
    Outcome
    No significant changeTolerability and deleterious effects
    Study

    n: not reported in source

    Outcome group
    Adverse events · Whole body
    Studied dose
    250 mg per day · oral · 6 or 12 weeksAs given in this study (human).

    Source sentences

    Summary
    Chronic NMN supplementation was well tolerated and caused no significant deleterious effect.
    1 context sentence
    Summary · context
    We administered 250 mg NMN per day to aged men for 6 or 12 weeks in a placebo-controlled, randomized, double-blind, parallel-group trial.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In healthy older men, oral NMN significantly increased whole blood NAD concentrations.

    In plain wordsIn healthy older men, oral NMN increased blood NAD levels.

    Peptide
    NMN (nicotinamide mononucleotide)
    Outcome
    IncreaseWhole blood NAD concentrations
    Study

    n: not reported in source

    Outcome group
    Pharmacokinetics · Whole body
    Studied dose
    250 mg per day · oral · 6 or 12 weeksAs given in this study (human).

    Source sentences

    Summary
    Metabolomic analysis of whole blood samples demonstrated that oral NMN supplementation significantly increased the NAD + and NAD + metabolite concentrations.
    1 context sentence
    Summary · context
    We administered 250 mg NMN per day to aged men for 6 or 12 weeks in a placebo-controlled, randomized, double-blind, parallel-group trial.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In healthy older men, oral NMN significantly increased whole blood NAD metabolite concentrations.

    In plain wordsIn healthy older men, oral NMN increased blood NAD metabolite levels.

    Peptide
    NMN (nicotinamide mononucleotide)
    Outcome
    IncreaseWhole blood NAD metabolite concentrations
    Study

    n: not reported in source

    Outcome group
    Pharmacokinetics · Whole body
    Studied dose
    250 mg per day · oral · 6 or 12 weeksAs given in this study (human).

    Source sentences

    Summary
    Metabolomic analysis of whole blood samples demonstrated that oral NMN supplementation significantly increased the NAD + and NAD + metabolite concentrations.
    1 context sentence
    Summary · context
    We administered 250 mg NMN per day to aged men for 6 or 12 weeks in a placebo-controlled, randomized, double-blind, parallel-group trial.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In healthy older men, NMN produced nominally significant improvements in gait speed that require validation in larger studies.

    In plain wordsIn healthy older men, NMN nominally improved walking speed, but larger studies must validate this result.

    Peptide
    NMN (nicotinamide mononucleotide)
    Outcome
    IncreaseGait speed
    Study

    n: not reported in source

    Outcome group
    Exercise and physical function · Whole body
    Studied dose
    250 mg per day · oral · 6 or 12 weeksAs given in this study (human).

    Source sentences

    Summary
    There were nominally significant improvements in gait speed and performance in the left grip test, which should be validated in larger studies;
    1 context sentence
    Summary · context
    We administered 250 mg NMN per day to aged men for 6 or 12 weeks in a placebo-controlled, randomized, double-blind, parallel-group trial.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In healthy older men, NMN nominally improved left grip test performance, which requires validation in larger studies.

    In plain wordsIn healthy older men, NMN nominally improved left grip performance, but larger studies must validate this result.

    Peptide
    NMN (nicotinamide mononucleotide)
    Outcome
    IncreaseLeft grip test performance
    Study

    n: not reported in source

    Outcome group
    Exercise and physical function · Whole body
    Studied dose
    250 mg per day · oral · 6 or 12 weeksAs given in this study (human).

    Source sentences

    Summary
    There were nominally significant improvements in gait speed and performance in the left grip test, which should be validated in larger studies;
    1 context sentence
    Summary · context
    We administered 250 mg NMN per day to aged men for 6 or 12 weeks in a placebo-controlled, randomized, double-blind, parallel-group trial.
  6. 06HumanRandomized controlled trialEfficacy outcome

    In healthy older men, NMN had no significant effect on body composition.

    In plain wordsIn healthy older men, NMN did not significantly change body composition.

    Peptide
    NMN (nicotinamide mononucleotide)
    Outcome
    No significant changeBody composition
    Study

    n: not reported in source

    Outcome group
    Body weight · Whole body
    Studied dose
    250 mg per day · oral · 6 or 12 weeksAs given in this study (human).

    Source sentences

    Summary
    however, NMN exerted no significant effect on body composition.
    1 context sentence
    Summary · context
    We administered 250 mg NMN per day to aged men for 6 or 12 weeks in a placebo-controlled, randomized, double-blind, parallel-group trial.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    21 Oct 2026, 15:58 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 12:50 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.